Imetelstat plus ruxolitinib for myelofibrosis patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 1 study tests whether imetelstat combined with ruxolitinib is safe and may improve disease activity in people with myelofibrosis. It is aimed at people who need symptom control and may be taking (or considered for) ruxolitinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a myelofibrosis type called primary myelofibrosis, or myelofibrosis after essential thrombocythemia or polycythemia vera
- Your risk level is intermediate-1, intermediate-2, or high based on a scoring system (DIPSS)
- You are a candidate for ruxolitinib, either already taking it steadily for at least 12 weeks or not yet treated with a JAK inhibitor (they stopped adding people to one group)
- You have active myelofibrosis symptoms measured by a symptom checklist (the threshold depends on your study group)
- You cannot (or do not want to) get a stem cell transplant at the start of the study
- You must meet blood test and other lab limits, and have good day-to-day function (performance status 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests whether adding a type of interferon (ropeginterferon) to your current myelofibrosis treatment (ruxolitinib) is safe and tolerable. Myelofibrosis is a blood disorder where bone marrow becomes scarred; this combination might help control the disease better.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.